TGA · AHPRA · FSANZ · ACCC
Last reviewed: September 2025
Online Pharmacy Advertising Compliance Australia 2025 — TGA · AHPRA · ACCC
Introduction
Online pharmacies move fast. A product range of several thousand SKUs, updated weekly, means marketing copy is being written and published at a pace that has no equivalent in traditional retail. The compliance problem is not unique to pharmacies — it's the same problem every Australian health brand faces — but online pharmacies face it at greater volume and with greater product complexity than almost anyone else.
The regulatory consequence of getting it wrong is significant. The TGA issued 4,806 removal requests in 2023–24 and 147 infringement notices totalling $2.20M. A meaningful proportion of those removal requests targeted digital product content — product pages, category landing pages, and email promotions — published by businesses that believed their copy was compliant. AHPRA assessed 775 advertising complaints in 2024–25, up 104% in two years, with specific enforcement attention on pharmacist-attributed content. The "I didn't realise" defence does not reduce penalties under either framework.
1. The regulatory framework for online pharmacy content
Online pharmacy advertising sits at the intersection of four frameworks that each operate independently.
Therapeutic Goods Act 1989, s.42DL — prohibited advertisements Section 42DL of the TGA Act creates an absolute prohibition on advertising Schedule 4 (prescription-only) and Schedule 8 (controlled) medicines to the general public. This is not a soft rule with exemptions for online channels — it is a criminal offence. The prohibition extends to product pages, search result snippets, meta descriptions, email subject lines, and any content a consumer can access without a verified prescription. A product page that displays the name, description, or properties of a Schedule 4 medicine in a consumer-facing context is a breach.
Therapeutic Goods Advertising Code 2021 — product claim requirements The Advertising Code governs how therapeutic goods (including Listed and Registered Medicines) can be advertised. Key requirements for online pharmacy content:
- Claims must not exceed the approved indications on the product's ARTG entry (s.8)
- Mandatory statements must appear in all consumer-directed advertising, including product pages: the AUST L or AUST R number, the sponsor name, and the statement 'Always read the label and follow the directions for use' (ss.14–16)
- Testimonials attributing health outcomes to a therapeutic good are prohibited (s.17)
- Restricted representations — claims relating to serious conditions including cancer, cardiovascular disease, and mental health conditions — require pre-approval from the Secretary (s.20–21)
AHPRA Advertising Guidelines — pharmacist-specific obligations Where a registered pharmacist is named or featured in advertising, or where the advertising is for a pharmacist's professional services (such as medication reviews, vaccination clinics, or clinical consultations), the AHPRA advertising guidelines apply in addition to TGA rules. Key obligations include the testimonial ban under s.133 of the National Law, and the prohibition on misleading claims about professional services.
Australian Consumer Law — pricing and representations All online pharmacy pricing and promotional content is subject to the ACL, particularly s.18 (misleading or deceptive conduct) and s.29 (false representations about goods and services). Specific applications include: was/now pricing, bundle offer conditions, PBS co-payment advertising, and any claim about the therapeutic benefits of products that is not substantiated.
2. Product page compliance — matching copy to ARTG-approved indications
The most frequently breached compliance area for online pharmacies is product page copy that exceeds the indications recorded on the product's ARTG entry.
Every Listed Medicine (AUST L) has a set of approved indications in the ARTG. These are the specific health statements the TGA has accepted as appropriate for that product. Marketing copy — product descriptions, feature bullets, category listing copy, and search result snippets — constitutes advertising under the Therapeutic Goods Advertising Code and must remain within these approved indications.
Common product page violations:
Expanded indication claims. An immune support supplement's ARTG entry states "to support immune system health." The product page describes it as "clinically formulated to strengthen your body's natural defences against infection." The second statement exceeds the approved indication and implies disease prevention — a prohibited claim under s.8 of the Advertising Code.
Ingredient-level efficacy claims. A product page lists the ingredients and then attributes specific health outcomes to individual ingredients that are not part of the product's registered indication. For example: "Contains zinc, which reduces the duration and severity of colds." If this claim is not supported by the product's approved indications, it is a breach — even if the underlying evidence about zinc is accurate.
AI-generated copy on ARTG-listed products. Online pharmacies increasingly use AI tools to generate product descriptions at scale. AI-generated copy frequently extrapolates health benefits beyond the product's approved indications, incorporating general ingredient research rather than the specific registered claims. Every AI-generated product page for an ARTG-listed product must be reviewed against the product's ARTG entry before publication.
What product page copy should do:
- Describe the product's uses in language that mirrors or stays within the approved indications
- Include the mandatory AUST L/R number, sponsor name, and 'always read the label' statement
- Avoid testimonials, clinical efficacy comparisons, or implied disease prevention claims
- Link to a full product label or Consumer Medicine Information where available
3. Category descriptions — what the rules allow at scale
Category pages on online pharmacy platforms aggregate products by condition, ingredient, or use type. Category-level copy creates a distinct compliance challenge because it makes claims about a product category rather than a specific product — and the advertising framework still applies.
Category descriptions as advertising. Under the Therapeutic Goods Advertising Code, a category page that promotes a range of therapeutic goods to consumers is an advertisement. Claims on that page are held to the same standard as claims on individual product pages. A category page titled "Cold and Flu Relief" with copy stating "fast, effective symptom relief for cold and flu" is making a therapeutic claim on behalf of all products listed on that page. Each of those claims must be substantiated and must not exceed the approved indications of the products in that category.
Prohibited representations in category copy. Category descriptions frequently contain restricted representations — implicit or explicit references to serious conditions that require regulatory pre-approval. Examples include: categories containing language around cardiovascular health ("supports heart health"), mental health ("for stress and anxiety relief"), or weight management ("clinically effective weight loss supplements"). These require review against s.20–21 of the Advertising Code.
PBS and OTC category advertising. Advertising price comparisons, co-payment structures, or PBS availability at the category level requires careful ACL compliance. "PBS medicines available" as a category descriptor is generally permissible. "PBS medicines cheaper here" without substantiation is a potential ACL breach.
4. Prescription copy — what online pharmacies cannot say
The prohibition on advertising Schedule 4 and Schedule 8 medicines to consumers is absolute. For online pharmacies, this means:
- Product pages for prescription medicines may display the product name for the purpose of patient-initiated search and repeat prescription fulfillment — but cannot include promotional copy, health benefit claims, or efficacy descriptions
- Promotional email campaigns cannot include Schedule 4 product names, descriptions, or pricing in consumer-facing communications
- Category pages titled with reference to prescription-only conditions or treatments (e.g. "Erectile Dysfunction Treatments") must be carefully structured so they do not constitute an advertisement for specific Schedule 4 products
- Remarketing campaigns cannot target consumers based on prescription product viewing history with promotional content about those products
The online pharmacy sector's use of condition-based landing pages — where a consumer searches for a condition and lands on a page describing treatment options — creates significant TGA risk if those treatment options include Schedule 4 medicines described in any promotional way.
5. Common online pharmacy compliance mistakes
MISTAKE — Publishing AI-generated product descriptions without ARTG review PROBLEM — AI tools generate compelling health copy by drawing on general ingredient and category research. For ARTG-listed products, this routinely produces copy that exceeds approved indications or implies unregistered health benefits. FIX — Implement a mandatory ARTG-check step before any AI-generated product page is published. Cross-reference the generated copy against the product's approved indications in the ARTG.
MISTAKE — Missing mandatory statements on product pages PROBLEM — Many online pharmacy product pages include health claims, ingredient information, and promotional copy but omit the mandatory AUST number, sponsor name, and 'always read the label' statement required under ss.14–16 of the Advertising Code. FIX — Implement mandatory statements as a hardcoded template element on all product page layouts for ARTG-listed products.
MISTAKE — Cross-sell and bundle copy implying combined therapeutic effect PROBLEM — Promotional copy for product bundles often implies a combined or enhanced therapeutic effect from taking multiple products together. For example: "The ultimate winter wellness stack — supercharge your immune defence." This claim about the bundle as a whole may not be supported by the individual products' ARTG entries. FIX — Bundle and cross-sell copy should be reviewed against the approved indications of each component product individually. Do not extrapolate combined effects.
Compliant vs non-compliant examples
❌ NON-COMPLIANT
"Boost your immune system and fight off colds and flu this winter with our best-selling immune defence formula — clinically proven to cut sick days in half. AUST L 123456."
✅ COMPLIANT
"Formulated to support immune system health. AUST L 123456. Always read the label and follow the directions for use."
❌ NON-COMPLIANT
Category page headline: "The best supplements for anxiety and depression — naturally calm your nervous system and restore your mood balance."
✅ COMPLIANT
Category page headline: "Nervous system support — supplements formulated to support general nervous system health. Always read the label and follow the directions for use."
❌ NON-COMPLIANT
"Bundle: The Ultimate Winter Stack — supercharge your immunity, stop infections before they start, and recover faster. Save 20% on our top-selling immune bundle."
✅ COMPLIANT
"Winter wellness bundle — formulated to support immune system health and general wellbeing. Individual products: see AUST L numbers on each label. Always read the label and follow the directions for use."
Penalty reference
| Regulator | Offence type | Individual max | Corporate max |
|---|---|---|---|
| TGA | Advertising a Schedule 4/8 medicine to consumers | $220,000 + imprisonment | $1.1M |
| TGA | Infringement notice (Advertising Code breach) | $19,800 | $19,800 |
| TGA | Civil/court penalty (Advertising Code) | $220,000 | $1.1M |
| ACCC / ACL | Misleading pricing or health claims | $2.5M | $50M |
Pre-publish checklist
TGA — Product pages (Listed Medicines)
Before you publish, check:
- □All health claims match the product's ARTG-approved indications
- □AUST L/R number present on every product page
- □Sponsor name present on every product page
- □"Always read the label and follow the directions for use" present on every product page
- □No testimonials attributing health outcomes to the product
- □No restricted representations (serious condition claims) without pre-approval
- □AI-generated copy reviewed against ARTG entry before publication
TGA — Schedule 4/8 products
Before you publish, check:
- □Product pages for Schedule 4/8 medicines contain no promotional copy
- □No email campaigns including Schedule 4 product names, descriptions, or pricing
- □Condition-based category pages do not constitute advertisements for specific Schedule 4 products
ACL / Pricing
Before you publish, check:
- □Was/now pricing reflects genuine prior prices with dates where relevant
- □PBS co-payment advertising accurate and not misleading
- □Bundle copy does not imply combined therapeutic effects not supported by individual ARTG entries
Related guides
→ Supplement & VDS Brand Advertising Compliance → Medical Device Advertising Compliance → What free tools do the TGA and AHPRA provide? → What mandatory statements are required on supplement advertising?
How CompliGUARD automates this check
CompliGUARD reviews online pharmacy marketing content — product page descriptions, category copy, email promotions, and search ad copy — against TGA · AHPRA · FSANZ · ACCC requirements simultaneously. For ARTG-listed products, CompliGUARD cross-references marketing copy against the product's specific approved indications, flagging claims that exceed the registered scope. Every review produces a clause-cited compliance report, a compliant rewrite, and a timestamped record stored in a tamper-evident audit vault. For online pharmacies managing hundreds or thousands of active SKUs, this means product copy can be reviewed at the speed of publication — not days later.
Key takeaways
- Product page copy for Listed Medicines must not exceed the approved indications recorded on the product's ARTG entry.
- Schedule 4 and Schedule 8 product pages cannot include promotional copy — only factual identification information for repeat prescription fulfillment.
- Category descriptions constitute advertising under the Therapeutic Goods Advertising Code and are subject to the same claim requirements as individual product pages.
- Mandatory statements — AUST number, sponsor name, and 'always read the label' — are required on all product pages for ARTG-listed therapeutic goods.
- AI-generated product copy for ARTG-listed medicines must be reviewed against product-specific approved indications before publication.
Regulatory references
- Therapeutic Goods Act 1989 (Cth), s.42DL (prohibited advertisements — scheduled medicines)
- Therapeutic Goods Advertising Code 2021 (Cth), s.8 (prohibited representations — general)
- Therapeutic Goods Advertising Code 2021 (Cth), ss.14–16 (mandatory statement requirements)
- Therapeutic Goods Advertising Code 2021 (Cth), s.17 (testimonial restrictions)
- Therapeutic Goods Advertising Code 2021 (Cth), ss.20–21 (restricted representations)
- Health Practitioner Regulation National Law Act 2009, s.133 (AHPRA testimonial ban)
- Australian Consumer Law (Schedule 2, Competition and Consumer Act 2010), s.18 and s.29
CompliGUARD provides compliance insights based on TGA, FSANZ, ACCC and AHPRA guidance as current at the time of review. The Therapeutic Goods Advertising Code is currently under formal review by the TGA (2025–26). This output does not constitute legal advice.